Last updated: May 3, 2024
Sponsor: Sanguine Biosciences
Overall Status: Active - Recruiting
Phase
N/A
Condition
Celiac Disease
Hepatitis
Thalassemia
Treatment
Specimen sample
Clinical Study ID
NCT05635266
SAN-BB-02
Ages 18-85 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Persons 18 to 85 years of age at the date of informed consent.
- If presenting with a history of a specific condition, the diagnosis is confirmable inthe medical record or may be confirmed using other forms of verification includingself-reporting.
- Understands the procedures and requirements of the study by providing written informedconsent (or verbal assent if a legally authorized representative will sign the ICF),including consent for authorization for protected health information disclosure.
Exclusion
Exclusion Criteria:
- Persons younger than 18 years of age or older than 85 years of age at the date ofinformed consent.
- Receipt of blood products 30 days before the study blood draw.
- Receipt of an investigational (unapproved) drug 30 days before the study blood draw.
- A confirmable diagnosis of any medical condition that would increase potentialphlebotomy risks.
- Has donated a unit of blood within the last 2 months at the date of informed consent.
Study Design
Total Participants: 20000
Treatment Group(s): 1
Primary Treatment: Specimen sample
Phase:
Study Start date:
October 26, 2021
Estimated Completion Date:
October 31, 2025
Connect with a study center
Sanguine Biosciences
Waltham, Massachusetts 02451
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.